|
Shares of Abbott Laboratories rose Thursday after regulators approved its drug-coated Xience V stent for sale. The Food and Drug Administration approved the stent late Wednesday, and Abbott expects it to take between 25 percent and 30 percent of the U.S. drug-coated stent market over the next 12 months. |
|
Read more...
|